The short version of reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
This delivery method gained worldwide recognition during COVID-19 pandemic with the approval of mRNA vaccines from Pfizer-BioTech and Moderna. The rapid rollout of these vaccines proved that LNPs are not only effective but also scalable for mass production and global use. Looking beyond vaccines, mRNA therapies are now being explored for a range of therapeutic applications including cancer immunotherapy, genetic disorders, and other infectious diseases. Researchers are also testing alternative delivery systems, like exosomes and new types of nanoparticles, to make mRNA therapies safer and more efficient. However, challenges remain, as mRNA is highly sensitive to environmental conditions. To address this, ongoing research is expanding into new administration routes including inhalable or oral mNRA formulations. This could reduce production costs and make these therapies more accessible to the world.
== Technology == Dr. Werner Baumgartner was responsible for founding Psychemedics and spearheading its initial research. A nationally recognized expert on drug testing through hair samples, Dr. Baumgartner gained acclaim by procuring some strands of hair from the 19th-century poet John Keats. Despite the age of the hair, Baumgartner was able to detect that the poet, who died at the age of 26 from tuberculosis, had been taking an increasing amount of opium before his death, most likely used in painkillers. Dr. Baumgartner's find created a minor sensation, enough to warrant a mention in a 1985 Time magazine cover story about drugs in the workplace. After years of research proved that drugs deposited in the hair can be accurately measured, the company was formed in 1987 and pioneered the use of hair testing in commercial markets including banks, manufacturers, retailers, mining operations, hotels and casinos. The technology capitalizes on the way the body metabolizes ingested drugs as they flow through the blood stream and deposit in the cortex of the hair. Hair is stable and the deposits are permanently embedded in the hair, so hair acts like a tape recorder — “recording” drug deposits in proportion to use over time as drugs are deposited in proportion to use. Hair grows at approximately the rate of ½ an inch per month and takes about 5 days to grow out past the external layer of skin. Psychemedics’ standard test uses a 1 ½ inch sample of head hair, which provides an approximate 3 month history of drug use. Body hair can also be collected if head hair is not available.
It is highly efficient. As the figure demonstrates, the number of peptides formed in the synthetic process (3, 9, 27, 81) increases exponentially with the number of executed cycles. Using 20 amino acids in each synthetic cycle, the number of formed peptides are 400, 8,000, 160,000 and 3,200,000, respectively. This means that the number of peptides increases exponentially with the number of the executed cycles. All peptide sequences that are formed in the process can be deduced by a combination of the amino acids used in the cycles. Portioning of the support into equal samples assures formation of the components of the library in nearly equal molar quantities. Only a single peptide forms on each bead of the support. This is the consequence of using only one amino acid in the coupling steps. It is completely unknown, however, which is the peptide that occupies a selected bead. The split-mix method can be used for the synthesis of organic or any other kind of library that can be prepared from its building blocks in a stepwise process. In 1990, three groups described methods for preparing peptide libraries by biological methods and one year later Fodor et al. published a remarkable method for synthesis of peptide arrays on small glass slides. A "parallel synthesis" method was developed by Mario Geysen and his colleagues for preparation of peptide arrays. They synthesized 96 peptides on plastic rods (pins) coated at their ends with the solid support. The pins were immersed into the solution of reagents placed in the wells of a microtiter plate.
Sources: en.wikipedia.org
The president is directly elected by popular vote for a renewable six-year term. Requirements for this position, which were enacted by the PAP government, are extremely stringent, such that only a handful of people qualify for the candidacy. These qualifications include that a candidate needs to be a person at least 45 years of age who is no longer a member of a political party, to either have held public office for at least 3 years in a number of specific public service leadership roles, or to have 3 years experience as chief executive of a fully profitable private sector company with at least S$500 million in shareholders' equity, be a resident in Singapore for at least 10 years, not have a criminal record, and more. Candidates must also "satisfy" the Presidential Elections Committee (PEC) that they are a person of integrity, good character and reputation. From 2017, the Constitution requires that presidential elections be "reserved" for a racial community if no one from that ethnic group has been elected to the presidency in the five most recent terms. Only members of that community may qualify as candidates in a reserved presidential election. In the 2017 presidential election, this combination of stringent requirements and a reserved election that required the candidate to be of the 13% Malay ethnic group led to the PEC approving a single candidate for the presidency; Halimah Yacob, considered part of the Malay community, won in an uncontested election. She also became Singapore's first female president.
Many mammalian species have developed keratinized penile spines along the glans or shaft, which may be involved in sexual selection. These spines have been described as being simple, single-pointed structures (macaques) or complex with two or three points per spine (strepsirrhines). Penile spine morphology may be related to mating system.
The many-banded krait (Bungarus multicinctus) is the second most venomous krait species known, based on toxinological studies conducted on mice. The venom of the many-banded krait consists of both pre- and postsynaptic neurotoxins (known as α-bungarotoxins and β-bungarotoxins, among others). Due to poor response to antivenom therapy, mortality rates are very high in cases of envenomation – up to 50% of cases that receive antivenom are still fatal. Case fatality rates of the many-banded krait envenoming reach 77–100% without treatment. The average venom yield from specimens kept on snake farms was between 4.6 and 18.4 mg per bite. In another study, the average venom yield was 11 mg (Sawai, 1976). The venom is possibly the most toxic of any Bungarus (krait) species and possibly the most toxic of any snake species in Asia, with LD50 values of 0.09 mg/kg–0.108 mg/kg SC, 0.113 mg/kg IV and 0.08 mg/kg IP on mice. Based on several LD50 studies, the many-banded krait is among the most venomous land snakes in the world. The Taiwan National Poison Control Center reports that the chief cause of death from snakebite during the decade (2002–2012) was respiratory failure, with 80% of these caused by bites from the many-banded krait.
Sources: en.wikipedia.org
=== 2002–2005: Lilo & Stitch, The Ring, and television success === Chase's international profile expanded significantly in 2002. She was cast as the voice of Lilo Pelekai, a quirky and lonely Hawaiian girl who befriends a destructive alien fugitive, in the Walt Disney Animation Studios feature Lilo & Stitch. The film was a critical and commercial triumph, grossing over $273 million worldwide. Chase's voice performance was highly praised for its emotional authenticity and comedic timing; she was subsequently awarded the Outstanding Voice Acting in an Animated Feature at the 30th Annie Awards in 2003. She reprised the role of Lilo in the direct-to-video film Stitch! The Movie (2003) and the subsequent television series Lilo & Stitch: The Series, which aired on the Disney Channel from 2003 to 2006. Another voice acting role followed that year in Hayao Miyazaki's acclaimed animated fantasy film Spirited Away, that had a Disney-produced English-language dub where Chase provided the voice for protagonist Chihiro Ogino. Spirited Away later won the Academy Award for Best Animated Feature. Later in 2002, Chase starred as Samara Morgan in the supernatural horror film The Ring, a remake of the 1998 Japanese film Ring. Playing a malevolent, drowned child who curses a videotape, Chase required extensive prosthetic makeup and performed physically demanding stunt work in the role. Her portrayal gained wide notice in early 2000s pop culture, and the character of Samara became an iconic cinematic villain. At the 2003 MTV Movie Awards, Chase won the Best Villain award.
==== Drawbacks ==== This mechanism for resolving biological homochirality relies heavily on the prebiotic synthesis of RAO, and assumes that it is the prebiotic precursor to nucleic acids. The crystallization efficiency of compounds depends on their concentration, and RAO would need to be saturated in solution for enantioselective crystallization to occur. This could be achieved through frequent wet-dry cycles, which would also remove diastereomers of RAO which are also produced in prebiotic reactions and can modify its crystal habit.
Caffeine can produce a mild form of drug dependence – associated with withdrawal symptoms such as sleepiness, headache, and irritability – when an individual stops using caffeine after repeated daily intake. Tolerance develops to autonomic effects (blood pressure, heart rate, nervousness) and to alerting/vigilance benefits with regular use. Chronic exposure upregulates adenosine receptors, raising the effort threshold for allocating attention—even to mundane or previously enjoyable tasks—because habitual users operate from a lowered arousal baseline. Caffeine is classified by the US Food and Drug Administration (FDA) as generally recognized as safe. Lethal doses, over 10 grams per day for an adult, greatly exceed the typical dose of under 500 milligrams per day. The European Food Safety Authority reported that up to 400 mg of caffeine per day (around 5.7 mg/kg of body mass per day) does not raise safety concerns for non-pregnant adults, while intakes up to 200 mg per day for pregnant and lactating women do not raise safety concerns for the fetus or the breast-fed infants. A 6 ounce cup of coffee typically contains 50–175 mg of caffeine, depending on what "bean" (seed) is used (and how much), how it is roasted, and how it is prepared (e.g., drip, percolation, or espresso). Thus roughly 50–100 ordinary cups of coffee would be required to reach a lethal dose. However, pure powdered caffeine, which is available as a dietary supplement, can be lethal in tablespoon-sized amounts.
The dissolution of collagen depends on time, temperature, and environmental pH. At high temperatures, the rate of collagen loss will be accelerated, and extreme pH can cause collagen swelling and accelerated hydrolysis. Due to the increase in porosity of bones through collagen loss, the bone becomes susceptible to hydrolytic infiltration where the hydroxyapatite, with its affinity for amino acids, permits charged species of endogenous and exogenous origin to take up residence. The hydrolytic activity plays a key role in the mineral phase transformations that expose the collagen to accelerated chemical- and bio-degradation. Chemical changes affect crystallinity. Mechanisms of chemical change, such as the uptake of F− or CO2−3 may cause recrystallization where hydroxyapatite is dissolved and re-precipitated allowing for the incorporation or substitution of exogenous material. Once an individual has been interred, microbial attack, the most common mechanism of bone deterioration, occurs rapidly. During this phase, most bone collagen is lost and porosity is increased. The dissolution of the mineral phase caused by low pH permits access to the collagen by extracellular microbial enzymes thus microbial attack.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.